Arrowhead granted Alnylam an exclusive, worldwide license to use Dynamic Polyconjugate (DPC) delivery technology for an undisclosed RNAi therapeutic product

Arrowhead Research Corp.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Alnylam Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$448.1m on 01/14/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced